Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL)
M Demierre, S Whittaker, Y Kim, E Kim… - Journal of Clinical …, 2009 - ascopubs.org
8546 Background: Romidepsin is a novel pan-HDAC inhibitor with demonstrated single-
agent activity in 2 open-label clinical studies of 167 patients (pts) with CTCL [mycosis …
agent activity in 2 open-label clinical studies of 167 patients (pts) with CTCL [mycosis …
Romidepsin for the treatment of T-cell lymphomas
AL McGraw - American journal of health-system pharmacy, 2013 - academic.oup.com
Purpose The pharmacology, pharmacokinetic and pharmacodynamic properties, and
clinical data on a novel therapy for the treatment of cutaneous or peripheral T-cell lymphoma …
clinical data on a novel therapy for the treatment of cutaneous or peripheral T-cell lymphoma …
Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL).
Abstract Abstract 1657 Poster Board I-683 Background The histone deacetylase (HDAC)
inhibitors are a class of epigenetic agents undergoing clinical testing. HDAC inhibitors …
inhibitors are a class of epigenetic agents undergoing clinical testing. HDAC inhibitors …
[HTML][HTML] Results of a Phase 2 NCI Multicenter Study of Romidepsin in Patients with Relapsed Peripheral T-Cell Lymphoma (PTCL).
Background: The histone deacetylase (HDAC) inhibitors are a class of epigenetic agents
undergoing clinical testing. HDAC inhibitors modulate expression of genes involved in cell …
undergoing clinical testing. HDAC inhibitors modulate expression of genes involved in cell …
[HTML][HTML] A phase Ib trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the Ro-CHOP study
J Dupuis, RO Casasnovas, H Ghesquieres… - Blood, 2012 - Elsevier
Abstract Abstract 1617 Background: Romidepsin is a selective class 1 histone deacetylase
inhibitor approved by the FDA for patients with cutaneous T-cell lymphoma and PTCL who …
inhibitor approved by the FDA for patients with cutaneous T-cell lymphoma and PTCL who …
Romidepsin for the treatment of non-Hodgkin's lymphoma
VY Yazbeck, S Grant - Expert opinion on investigational drugs, 2015 - Taylor & Francis
Introduction: Patients with relapsed or refractory lymphoma remain a population with unmet
medical needs. Histone deacetylase inhibitors (HDACIs) represent a novel class of …
medical needs. Histone deacetylase inhibitors (HDACIs) represent a novel class of …
Phase I trial of a new schedule of romidepsin in patients with advanced cancers
L Amiri-Kordestani, V Luchenko, CJ Peer… - Clinical Cancer …, 2013 - AACR
Purpose: Romidepsin is a potent histone deacetylase inhibitor (HDI) with activity in T-cell
lymphoma. Given preclinical data showing greater induction of gene expression with longer …
lymphoma. Given preclinical data showing greater induction of gene expression with longer …
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
RP Whitehead, C Rankin, PMG Hoff, PJ Gold… - Investigational new …, 2009 - Springer
Introduction: Patients with metastatic colorectal cancer who progress on standard
chemotherapy have limited treatment options. New and effective drugs are needed for these …
chemotherapy have limited treatment options. New and effective drugs are needed for these …
Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma
S Woo, ER Gardner, X Chen, SB Ockers, CE Baum… - Clinical cancer …, 2009 - AACR
Purpose: Romidepsin is a potent histone deacetylase inhibitor under clinical development.
The objective of this study was to evaluate the effect of demographic, clinical, and …
The objective of this study was to evaluate the effect of demographic, clinical, and …
[HTML][HTML] Final analysis of the RO-CHOP phase Ib/II study: romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL)
J Dupuis, F Morschhauser, H Ghesquieres, H Tilly… - Blood, 2014 - Elsevier
Background: Romidepsin is a histone deacetylase inhibitor approved by the FDA for patients
with cutaneous T-cell lymphoma and PTCL who have received at least 1 prior therapy. In …
with cutaneous T-cell lymphoma and PTCL who have received at least 1 prior therapy. In …